Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Yashuhiro Sakemoto
Cancer immunotherapy has demonstrated great ability in recent
years, marked by a surge in the approval of immuno-oncology
drugs. Alongside this progress, the field of nucleic acid
therapeutics has also made significant advancements. These
therapies, including plasmids, Anti Sense Oligonucleotides
(ASO), small interfering Ribo Nucleic Acid (siRNA), microRNA,
messenger Ribo Nucleic Acid (mRNA), immunomodulatory
Deoxy Ribo Nucleic Acid (DNA)/ Ribo Nucleic Acid (RNA) and
gene-editing guide Ribo Nucleic Acid (gRNA), have become
appealing due to their ability to modify the expression of
endogenous or synthetic genes and regulate immune responses.
Published Date: 2024-11-21; Received Date: 2024-10-21